NurExone (TSXV:NRX) has created an exosome-based drug-delivery platform and is developing a novel therapy for acute spinal cord injuries. The post A next-generation...
Researchers used single-cell RNA sequencing (scRNA-seq) to identify a pattern of gene expression that can predict whether or not neurons will regenerate...
Clinical stage artificial intelligence (AI) drug discovery company Insilico Medicine (“Insilico”) has been invited to present scientific data on its...
A technique developed by University of Texas at Dallas and UT Southwestern Medical Center researchers to deliver medication through the blood-brain barrier...
Removing a patient’s tumor while sparing healthy tissue requires exquisite precision, but often surgeons must rely on their eyes and hands to determine...
Neurons, the main cells that make up our brain and spinal cord, are among the slowest cells to regenerate after an injury, and many neurons fail...
Lonza’s Synaffix is adding another manufacturing licensing partnership by securing a $740 million deal with Sotio Biotech, which would allow Sotio to...
Lonza’s Synaffix is adding another manufacturing licensing partnership by securing a $740 million deal with Sotio Biotech, which would allow Sotio to...
Reston, VA—A novel therapeutic approach that combines human epidermal growth receptor factor 2 (HER2)-targeted therapies with the cholesterol-lowering...
Astria Therapeutics revealed it had licensed Ichnos Sciences’ lead candidate for atopic dermatitis for an upfront fee of $15 million before announcing...
Data from a year-long Phase I clinical trial suggest that a donor regulatory dendritic cell therapy for people who are receiving liver transplants can...
The company TNC Terapia brings therapeutic nutrition to patients with solid tumours, seeking to enhance cancer treatments for the first time by applying...
In releasing second-quarter results in August, Prime Medicine conveyed the possibility of a first trial for its gene editing technology next year by publicly...
Gene therapies, antibody fragments, and microRNA drug products are being developed to counter cardiovascular disease mechanisms The post New Drugs May...
Atomwise entered a new phase of its journey as a company this week with the nomination of its first AI-driven development candidate, a small molecule focused...
After stepping into the CEO post for the first time about two years ago, taking over the helm of “tissue therapeutics” startup Satellite Bio, Dave...
Atsena Therapeutics has reduced its staff, is looking for a partner and has reeled in more cash from existing investors, the gene therapy biotech told...
Searching for new ways to block the growth of cancer cells is like looking for a needle in a haystack. Tumor cells rely on thousands of...
Healthcare stocks to watch right now. The post What Are The Best Stocks To Invest In? 2 Healthcare Stocks To Know appeared first on Stock Market...
Sponsored content brought to you by The landscape of regenerative medicine is evolving rapidly and changing the paradigm of healthcare. Potential cures,...
The New York Blood Center Enterprises (NYBCe) is absorbing two of Talaris Therapeutics’ autologous and allogeneic cell and gene therapy facilities to...
A research team, led by Professor Ja Hyoung Ryu from the Department of Chemistry at UNIST, in collaboration with Professor Hyewon Chung from Konkuk University,...
The New York Blood Center (NYBC) is absorbing two of Talaris Therapeutics’ autologous and allogeneic cell and gene therapy facilities to expand its CDMO...
Kezar Life Sciences, a 2015 spinout from Amgen, is laying off 41% of its workforce and pausing all preclinical R&D in a bid to extend its...
The FDA cleared Novavax’s updated Covid-19 booster for the fall season on Tuesday, weeks after mRNA boosters secured an authorization. Novavax made clear...
AI drug discovery and development company Exscientia is stopping a solid tumor trial as it refocuses its internal pipeline amid plans to ink another partnership...
After the usual 30-day review period, the Food and Drug Administration (FDA) placed GH Research’s GHRS Investigational New Drug (IND) application...
After a decade at the helm, Nancy Simonian will depart Syros Pharmaceuticals as the biotech works through a pivotal cancer study and adjusts after losing...
Chris Dokomajilar The biotech IPO market crashed hard last year, but we’re seeing the window creak open in a steady upward trend in 2023 that bodes...
COVID-19 Vaccine Found In The Hearts Of Dead People: Study Authored by Zachary Stieber via The Epoch Times (emphasis ours) COVID-19 vaccine...